Dr. Guy M. Middleton, M.D.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 27
Licensed in Alabama since 2003, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
AL license 25364 (first issued 2003; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- Southeast Health Medical Center Dothan, AL
Medical groups
- Dothan Obgyn, Inc. (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 27
- Services billed
- 418
- Patients’ average age
- 59
| Service | Times | Patients |
|---|---|---|
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Dothan, AL | 51 |
| Fluconazole Other prescribers in Dothan, AL | 19 |
| Clobetasol Propionate Other prescribers in Dothan, AL | 18 |
| Gemtesa (vibegron) Other prescribers in Dothan, AL | 15 |
| Metronidazole Other prescribers in Dothan, AL | 14 |
| Solifenacin Succinate Other prescribers in Dothan, AL | 13 |
| Osphena (ospemifene) | 12 |
| Progesterone (progesterone, micronized) Other prescribers in Dothan, AL | 12 |
| Clonidine Hcl Other prescribers in Dothan, AL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 11 payments worth $182 in total to this clinician.
| Solventum Corporation | $39.82 |
|---|---|
| Astellas Pharma US Inc | $36.24 |
| Exeltis, USA Inc. | $27.54 |
| Shield Therapeutics Inc | $24.73 |
| Sage Therapeutics, LLC | $21.09 |
| Pfizer Inc. | $16.94 |
| Sumitomo Pharma America, Inc. | $15.71 |
| Food and Beverage | $182 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $483,621 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
ModernaTX, Inc. · Completed · NCT06143046 - A phase 3 randomized placebocontrolled doubleblinded trial to evaluate the safety tolerability and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.